Home » Topics » Disease categories and therapies » Dental

Dental
RSS

Acacia Pharma initiates phase II study of locally administered xerostomia drug

July 25, 2011

PMX-30063 shows activity against oral mucositis in animal study

May 24, 2011

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

March 21, 2011

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Feb. 16, 2011

Oragenics plans second phase I trial of SMaRT replacement therapy

Feb. 2, 2011

Strativa launches Oravig in U.S. for oropharyngeal candidiasis

Aug. 25, 2010

Access Pharma and BioScrip sign MuGard distribution agreement

July 22, 2010

Sanofi-aventis and Novalar submit OraVerse MAA in five European countries

July 16, 2010

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

April 20, 2010

BioDelivery Sciences presents update on BEMA Buprenorphine

March 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...